LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-12-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Anemia (hematocrit <0.28) Thrombocytopenia (platelet count < 100 x 109/L) A significant platelet function defect other than aspirin Once anemia and thrombocytopenia have been excluded, further evaluation to exclude von Willebrand disease and inherited/acquired platelet dysfunction can be made.
== Nutrition and health claims == While peach gum contains dietary fiber and may have properties similar to other soluble fibers, many health claims about its benefits lack scientific evidence. Some research suggests it may have blood sugar-lowering effects similar to other plant-based dietary fibers, but more rigorous clinical studies are needed. Marketing claims about collagen content and anti-aging effects are not supported by scientific evidence, as plants do not produce collagen.
Rubidium is the second most electropositive of the stable alkali metals and has a very low first ionization energy of only 403 kJ/mol. It has an electron configuration of [Kr]5s1 and is photosensitive. Due to its strong electropositive nature, rubidium reacts explosively with water to produce rubidium hydroxide and hydrogen gas. As with all the alkali metals, the reaction is usually vigorous enough to ignite metal or the hydrogen gas produced by the reaction, potentially causing an explosion. Rubidium, being denser than potassium, sinks in water, reacting violently; caesium explodes on contact with water. However, the reaction rates of all alkali metals depend upon surface area of metal in contact with water, with small metal droplets giving explosive rates. Rubidium has also been reported to ignite spontaneously in air.
In the 1950s–1960s, freeze drying began to be viewed as a multi-purpose tool for both pharmaceuticals and food processing. In 2020, freeze dried candy saw a major surge in popularity in the USA due to viral popularity on social media with freeze dried versions of popular candies such as Skittles, Nerd Gummy Clusters, and SweeTarts appearing in stores.
For example, for an amino acid sequence (there are 20 "standard" amino acids that make up proteins), you would find there are 208 parameters. However, when studying coding regions of the genome, it is more common to work with a codon substitution model (a codon is three bases and codes for one amino acid in a protein). There are
Sources: en.wikipedia.org
== Company history == Digico was founded in 1965 by Keith Trickett and Avo Hiiemae, two ex-ICL electronics engineers. Former MP Eric Lubbock was chairman from 1969 to 1983. The company was based in Letchworth initially, moving to a new factory in Stevenage in 1973 and employing about 90 staff. Digico's first product was a laboratory data-logging and spectrum analyser hardware system named DIGIAC. A prototype had been developed before Digico was formed, by the founders in a garage, so became an immediate source of income. Digico soon developed a 16-bit minicomputer series, the Micro 16, for which it was best known for. In 1974 Digico had a turnover of over £1 million (equivalent to £9 million in 2025) and in 1977 well over £1 million. Spanverne Investments raised a large private capital investment into Digico in 1981, while the new Prince product was being developed. In October 1982, Digico announced it would close its Stevenage factory with the loss of 130 jobs within six months. This was part of a rationalisation plan to concentrate manufacturing at its large Leeds site. It would retain its Letchworth site primarily as a south England office. On 1 February 1984, the Financial Times reported that after a weekend of failed negotiation between British computer company Optim and Midland Bank, Digico went into receivership on 30 January 1984. Digico owed more that £400,000 to Midland Bank and over £1 million to other creditors.
The club was founded by members of the Royal Agricultural Society, the Melbourne Hunt Club and the Victorian Woolbrokers. The Essendon Football Club is thought to have been formed in 1872 at a meeting in the home of a well-known brewery family, the McCrackens, whose Ascot Vale property hosted a team of local junior players. Robert McCracken (1813–1885), the owner of several city hotels, was the founder and first president of the Essendon Football Club, and his son, Alex McCracken, its first secretary. Alex later became president of the newly formed VFL. Alex's cousin Collier McCracken, who had already played with Melbourne, was the team's first captain. The club played its first recorded match against the Carlton Second Twenty (the reserves) on 7 June 1873, with Essendon winning by one goal. Essendon played 13 matches in its first season, winning seven, with four draws and losing two. The club was one of the inaugural junior members of the Victorian Football Association (VFA) in 1877, and it began competing as a senior club from the 1878 season. During its early years in the Association, Essendon played its home matches at Flemington Hill, but it moved to the East Melbourne Cricket Ground in 1881. In 1878, at Flemington Hill, Essendon played its first match on what would be considered by modern standards to be a full-sized field. In 1879, Essendon played Melbourne in one of the earliest night matches recorded when the ball was painted white.
== Prevention == Tooth extraction is the major risk factor for development of MRONJ. Prevention including the maintenance of good oral hygiene, comprehensive dental examination and dental treatment including extraction of teeth of poor prognosis and dentoalveolar surgery should be completed prior to commencing any medication which is likely to cause osteonecrosis (ONJ). Patients with removable prostheses should be examined for areas of mucosal irritation. Procedures which are likely to cause direct osseous trauma, e.g. tooth extraction, dental implants, complex restoration, deep root planning, should be avoided in preference of other dental treatments. There are limited data to support or refute the benefits of a drug holiday for osteoporotic patients receiving antiresorptive therapy. However, a theoretical benefit may still apply for those patients with extended exposure histories (>4 yr), and current recommendations are for a 2 month holiday for those at risk. There was low quality evidence suggesting taking antibiotics prior to the dental extraction, as well as the use of post operative techniques for wound closure lowered the risk of patients developing medication-related osteonecrosis of the jaw compared with the usual standard care received for regular dental extractions. Post operative wound closure has been suggested to prevent the contamination of the underlying bone. More evidence is needed to assess the use of antibiotics prior to treatment and the use of wound closure to prevent contamination of the bone, as the quality of evidence evaluated was low.
=== Mechanical refrigeration === In the latter half of the 20th century, mechanical refrigeration began to replace ice-based systems. Soon after, mechanical refrigeration units replaced the armies of personnel required to re-ice the cars. The sliding plug door was experimentally introduced by P.F.E. (Pacific Fruit Express) in April 1947, when one of their R-40-10 series cars, #42626, was equipped with it. P.F.E.'s R-40-26 series reefers, designed in 1949 and built in 1951, were the first production series cars to be so equipped. In addition, the Santa Fe Railroad first used plug doors on their SFRD RR-47 series cars, which were also built in 1951. This type of door provided a larger six-foot opening to facilitate loading and unloading cars. These tight-fitting doors were better insulated and could maintain an even temperature inside the car. By the mid-1970s, the few remaining ice bunker cars were relegated to "top-ice" service, where crushed ice was applied atop the commodity.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.